Home » Topics » BioWorld Science

BioWorld Science
RSS

Boehringer Ingelheim and Yuhan collaborate on GLP1R/FGF21R agonist for NASH

July 2, 2019

Boston Biomedical to discontinue CanStem111P study of napabucasin in pancreatic cancer

July 2, 2019

European Commission approves Libtayo for advanced cutaneous squamous cell carcinoma

July 2, 2019

Shanghai Meiyue Biotech presents new thrombin inhibitors

July 2, 2019

Esteve Pharmaceuticals patent describes analgesic agents

July 2, 2019

GlaxoSmithKline synthesizes new IDO1 inhibitors

July 2, 2019

Parkinson's disease starts in gut, moves to brain: study

July 2, 2019

Boehringer Ingelheim patents GluN2B negative allosteric modulators

July 2, 2019

SciFluor Life Sciences divulges KCNQ2/3 activators

July 2, 2019

Results from phase II study presented for sintilimab in patients with R/R ENKTL

July 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...